NCT00397033View on ClinicalTrials.gov

Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.

PHASE3CompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Schizoaffective DisorderPsychotic Disorder
Interventions
DRUG

Paliperidone ER

6mg/day paliperidone er for 6 weeks

DRUG

Paliperidone ER

12mg/day paliperidone er for 6 weeks

DRUG

Placebo

Placebo for 6 weeks

All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00397033 - Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder. | Biotech Hunter | Biotech Hunter